Sandy Spring Bancorp, Inc., (Nasdaq:SASR) the parent company of Sandy Spring Bank, recently announced net income available to common stockholders for the third quarter of 2010 of $6.4 million ($0.27 per diluted share) compared to a net loss available to common stockholders of $14.8 million (($0.90) per diluted share) for the third quarter of 2009 and net income available to common stockholders of $5.1 million ($0.21 per diluted share) for the second quarter of 2010.
The third quarter of 2010 included a provision for loan and lease losses of $2.5 million compared to $34.5 million for the third quarter of 2009 and $6.1 million for the second quarter of 2010.
Sandy Spring Bancorp, Inc. operates as the holding company for Sandy Spring Bank, which offers a range of commercial banking, retail banking, and trust services to individuals and businesses in Maryland.
Sangamo BioSciences, Inc. (Nasdaq:SGMO) today reported third quarter 2010 financial results and accomplishments. For the third quarter ended September 30, 2010, Sangamo reported a consolidated net loss of $8.7 million, or $0.19 per share, compared to a net loss of $4.9 million, or $0.12 per share, for the same period in 2009.
As of September 30, 2010, Sangamo BioSciences had cash, cash equivalents, marketable securities and interest receivable of $63.1 million. Revenues for the third quarter of 2010 were $2.9 million, compared to $4.1 million for the same period in 2009.
Sangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and modification.
Sanmina-SCI Corporation (Nasdaq:SANM) announced previously that it will host its fiscal 2010 fourth quarter earnings conference call on Monday, November 1, 2010 at 5:00 p.m. ET. Mr. Jure Sola, Chairman and Chief Executive Officer of Sanmina-SCI Corporation, will lead the call.
What: Sanmina-SCI Corporation's Fiscal 2010 Fourth Quarter Earnings, Web Link: sanmina-sci.com, Teleconference Information: Dial in Number: 877.273.6760 – Domestic, 706.634.6605 – International, Contact: Sanmina-SCI Investor Relations at +1.408.964.3610
Sanmina-SCI Corporation is a leading electronics contract manufacturer serving the fastest growing segments of the global Electronics Manufacturing Services (NYSE:EMS) market.
Sanofi-aventis (NYSE:SNY) reported the initiation of a multinational Phase III study evaluating the efficacy and safety of two doses of once daily teriflunomide (7mg or 14mg) versus placebo in patients with relapsing multiple sclerosis (RMS) treated with interferon beta (IFN beta). Teriflunomide is a novel oral disease modifier developed by sanofi-aventis which is being investigated in a large Phase III clinical development program. It includes studies of teriflunomide in monotherapy for the treatment of RMS and in clinically isolated syndrome as well as adjunct therapy.
Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone.
Signup for FREE Daily Stock Alerts From CRWEFinance.com/signup
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEFinance.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEFinance.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://crwefinance.com/disclaimer) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period.